[ad_1]
Purdue Pharma will no longer market its opiate-based products in Canada, in part because the government of this country is asking manufacturers to suspend all opioid marketing and advertising.
The beleaguered Stamford Company and other drug makers to deal with an apparently increasing number of lawsuits filed against it by cities and states for the promotion of the likes of OxyContin. The plaintiffs argue that such activity contributed to an opioid addiction crisis that cost thousands of lives and millions of dollars.
In a letter posted on his website, David Pidduck, CEO of Purdue, wrote: We are convinced that Canadian prescribers need the most up-to-date information, including the most recent guidelines, to so that their patients are treated appropriately. [TRADUCTION] "In the future," continued Pidduck. our opioid products for healthcare professionals will be reactively addressed through direct communication with experienced health professionals in our medical affairs department. "
In February, Purdue announced that it would stop marketing its prescription pain medications in the United States., PDF and Email" />
